Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

6.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.8K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same author

Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling.

Cancer causes & control : CCC·2026
Same author

US multicentre randomised controlled trial protocol: Comparing Analgesic Regimen Effectiveness and Safety after surgery trial for Kids (CARES for Kids).

BMJ open·2026
Same author

Interval appendectomy practices for complicated appendicitis in children: a systematic review from the APSA Outcomes and Evidence-Based Practice Committee.

Pediatric surgery international·2026
Same author

Postoperative Care and Management in Pediatric Hematology-Oncology Patients.

European journal of haematology·2026
Same author

Psychological Impact of Congenital Chest Wall Deformities Among Adolescents and Young Adults.

Children (Basel, Switzerland)·2026
Same journal

Peutz-Jeghers Syndrome and lung cancer: does the risk meet the threshold for lung cancer screening?

Familial cancer·2026
Same journal

Transitioning from the Prospective Lynch Syndrome Database (PLSD) to the International Lynch Syndrome Database (ILSD).

Familial cancer·2026
Same journal

Expanding access to hereditary cancer genetic testing: a quality improvement initiative of mainstreaming in a diverse urban gynecology clinic.

Familial cancer·2026
Same journal

When screentime fails: initiative to improve completion of hereditary cancer genetic testing after telemedicine counseling.

Familial cancer·2026
Same journal

The impact of international care networks on the clinical management of constitutional mismatch repair deficiency (CMMRD): a review of recent developments.

Familial cancer·2026
Same journal

Monoallelic NTHL1 p.(Gln90*) and cancer risk: evidence from a large Turkish cohort.

Familial cancer·2026
See all related articles

Related Experiment Video

Updated: Mar 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

ATM mutations for surgeons.

Sara A Mansfield1, Robert Pilarski2, Doreen M Agnese3

  • 1Department of General Surgery, The Ohio State University College of Medicine, Columbus, OH, USA.

Familial Cancer
|December 19, 2016
PubMed
Summary
This summary is machine-generated.

Genetic testing for ataxia-telangiectasia mutated (ATM) gene mutations identifies individuals at higher risk for breast cancer. This review clarifies cancer risks and management for heterozygous ATM carriers.

Keywords:
Ataxia-telangiectasia mutationBreast cancerGenetic screening

More Related Videos

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
08:41

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration

Published on: December 27, 2024

2.1K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
08:41

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration

Published on: December 27, 2024

2.1K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

2.4K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The ataxia-telangiectasia mutated (ATM) gene encodes a protein kinase crucial for DNA repair pathways.
  • ATM mutations are linked to an increased risk of hereditary breast cancer in heterozygous carriers.

Observation:

  • This study reviews two cases of heterozygous ATM mutation carriers.
  • Literature review focuses on cancer risks and management strategies for these individuals.

Findings:

  • Heterozygous carriers of ATM mutations face elevated risks for breast cancer.
  • Understanding these risks is crucial for early detection and intervention.

Implications:

  • Increased identification of at-risk patients through genetic testing necessitates clear management guidelines.
  • Breast surgeons play a vital role in the care of heterozygous ATM mutation carriers.
  • This review aims to inform clinical practice regarding the management of ATM mutation carriers.